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the effects of ﬂuticasone propionate (FP) and budesonide (BUD) on growth in
children. This randomised, double-blind study compared the effects on growth of FP
and BUD in children aged 6–9 years with persistent asthma.
Following a 6-month run-in period (without inhaled corticosteroids), patients
with normal growth velocity were randomised to 12 months’ treatment with FP
100 mg bd (n ¼ 114) or BUD 200 mg bd (n ¼ 119). Growth velocity was determined by
stadiometric height measurement. Lung function, asthma symptoms and use of relief
medication were also assessed.
Annualised mean growth velocity during run-in was comparable in the two groups
(FP: 5.9 cm/yr; BUD: 6.0 cm/yr). During the treatment period, adjusted mean
growth velocity was signiﬁcantly higher in the FP than the BUD group (5.5 cm/yr vs
4.6 cm/yr; Po0:001). Asthma control improved similarly in both treatment groups.
Bone mineral density and overnight urinary cortisol:creatinine ratios were similar in
the two groups. Drug-related adverse events were reported among 3% of FP-treated
children, compared with 2% for BUD.Elsevier Ltd. All rights reserved.
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Growth velocity with inhaled corticosteroids in children 119In conclusion, this study demonstrates that FP for childhood asthma has
signiﬁcantly less impact on childhood growth velocity than a therapeutically
equivalent dose of BUD.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Inhaled corticosteroids (ICS) are currently recom-
mended as ﬁrst-line maintenance therapy for
children with persistent asthma.1 Compared with
oral corticosteroids, they have a much reduced risk
of systemic effects such as impaired hypothalamic
pituitary-adrenal (HPA) axis function.2,3 Concerns
persist about the potential effects of ICS therapy on
childhood skeletal development, particularly with
long-term treatment.4,5 Evidence suggests that
signiﬁcant differences exist between ICS in terms
of their effects on growth,6 a ﬁnding that is
consistent with the pharmacological differences
between these drugs. Previous studies have shown
ﬂuticasone propionate (FP) has signiﬁcantly less
effect on growth than beclomethasone dipropio-
nate (BDP) and budesonide (BUD) at therapeutically
equivalent doses.7–10 The long-term effects of BUD
were investigated in the large-scale Childhood
Asthma Management Plan study11 and showed a
small but signiﬁcant reduction in growth velocity
compared with the placebo group, most evident in
the ﬁrst year of treatment. There have been no
large-scale comparisons of FP with BUD over a
medium-to-long-term period. The objective of this
study was, therefore, to compare the effect of 12
months’ treatment with therapeutically equivalent
doses of FP and BUD12 on growth velocity in
prepubescent children with mild-to-moderate per-
sistent asthma, using growth measurements per-
formed in accordance with recent evidence based
recommendations.13Subjects and methods
Study design
The study was a randomised, double-blind, double-
dummy, parallel-group and multi-centred carried
out between September 1999 and October 2001.
During the 26-week run-in period patients re-
mained on their existing medication (excluding
ICS or antileukotrienes) and had their previous
bronchodilator therapy replaced by inhaled salbu-
tamol (Ventolins). This allowed their need for ICS
treatment to be assessed, and a non-ICS growthrate to be determined to exclude children with
existing growth abnormalities.
They were then randomly assigned, after dis-
continuing any long-acting b2-agonists, to 52
weeks’ treatment with FP 100 mg twice daily [bd]
(Diskuss) or BUD 200 mg bd (Turbuhalers), taken
morning and evening. These doses were consistent
with treatment guidelines and a 2:1 dosing ratio of
BUD and FP which has previously been found to be
of equal efﬁcacy.12 Treatment numbers were
allocated consecutively in a 1:1 ratio, in accor-
dance with the randomisation schedule generated
using the GlaxoWellcome computer program ‘Pa-
tient Allocation for Clinical Trials’ (block size of 4).
Treatment packs were numbered and the alloca-
tions were not revealed to investigators or other
study participants until all analyses were complete.
Salbutamol was used ‘as required’ for relief of
asthma symptoms. Clinic visits 1–8 were scheduled
at weeks 26, 12, 0, 4, 16, 28, 40 and 52,
respectively, at which stadiometric height, pub-
ertal status, lung function and symptoms were
assessed by the local physician investigator.
The study was conducted in accordance with
good clinical practice guidelines and the Declara-
tion of Helsinki. Local ethics committee and
regulatory authority approvals were obtained at
each centre, all parents/guardians provided writ-
ten informed consent and children provided assent
when feasible and appropriate.Study population
Children aged 6–9 years were recruited from 35
centres (mainly secondary care) in 11 countries
(Argentina, Belgium, Canada, Chile, Colombia,
Greece, Hong Kong, Panama, Portugal, Slovakia
and the Ukraine).
Inclusion criteria for enrolment in the study were
persistent asthma for X6 months, a forced ex-
piratory volume in 1 s (FEV1) ofX60% predicted for
height and age,14 an improvement in peak expira-
tory ﬂow rate (PEFR) of X15% after inhalation of
200 mg of salbutamol, ability to use the Diskus and
the Turbuhaler correctly, no changes in asthma
medication and no treatment with ICS in the
previous 4 weeks. Subjects who had received oral
corticosteroids on 42 occasions or 412 days or
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previous 6 months were excluded. Children with a
known growth disorder, or history of glaucoma or
cataracts, were also excluded.
Recruitment was competitive so that patients
were screened and if eligible, randomised consecu-
tively until the randomisation target was reached.
Patients who were still in run-in when the rando-
misation target was reached were withdrawn from
the study and offered alternative treatment. For
randomisation to treatment, patients had to be
prepubescent (Tanner sexual maturity rating of 115)
and considered by the investigator to require ICS.
Height had to be between the 5th and 95th centiles
for their age and run-in growth velocity (rate of
change in height over time) between the 20th and
95th percentiles, as measured against standard
growth velocity curves.15 They could not have
received oral corticosteroids on 42 occasions or
412 days or a total dose 4210mg prednisone (or
equivalent) during the run-in period.Study assessments
Height measurements were taken in triplicate to
the nearest 1mm, using a standard calibrated
Harpenden stadiometer (Holtain Ltd, Crymych,
Wales), between 6.00 and 10.30 am at every clinic
visit. To standardise methodology across centres,
investigators were instructed to ensure that each
patient was measured by the same person wherever
possible throughout the study. Height was mea-
sured standing without shoes, with heels in contact
with an upright wall and the head held level (lower
border of the eye sockets in the same plane as the
external auditory meati). Subjects were asked to
stretch their necks in order to be as tall as possible.
Gentle upward pressure was applied under the
mastoid process where necessary and subjects were
required to stand away from the machine between
measurements (staff training was provided to
ensure correct methodology at each centre).
Calibration of the stadiometer was carried out
daily using the calibration bar provided.
Lung function (forced vital capacity [FVC], FEV1
and FEV1/FVC ratio) was assessed three times
during each clinic visit and the highest value
recorded. Morning and evening PEFRs (highest of
three attempts using a ‘‘Mini Wright’’ peak ﬂow
meter) were recorded on diary record cards for
1 week after each study visit, except for visits 3
and 8 where the cards were completed 1 week
before the visit. Day-/night-time symptom scores
and salbutamol use for symptom relief were also
recorded.All adverse events were documented and un-
scheduled asthma-related healthcare contacts
monitored. Asthma exacerbations were deﬁned as
‘mild’ if they required additional asthma medica-
tion (other than increased use of salbutamol) and
‘severe’ if systemic corticosteroids and/or hospital
treatment were required. Medication use (study
medication or other) was assessed by questioning
patients, recording on diary record cards and/or
examining patients’ medical notes. Ophthalmo-
scopic examinations were performed at visits 1, 3,
6 and 8. At every visit, patients were examined for
signs of oropharyngeal candidiasis and their vital
signs assessed.
Overnight 12-h urinary cortisol was measured at
randomisation and then at 6-month intervals by
high-performance liquid chromatography at a cen-
tral laboratory (Quest Diagnostics Ltd, Heston, UK),
and expressed as nmol/umol creatinine. Urine
samples were stored at 20 1C and shipped frozen.
Lumbar-spine bone mineral density (BMD) was
assessed at the beginning and end of treatment
by dual-energy X-ray absorptiometry, in those
patients attending centres with access to the
required equipment. BMDs were not obtained
during the run-in phase as it was deemed unethical
to expose children to radiation when it was
uncertain that they would enter the randomization
phase.Statistical analysis
The primary objective was to determine if treat-
ment with FP would cause less suppression of
growth velocity over 12 months than a similarly
efﬁcacious dose of BUD, by comparing the growth
velocities of children between the two treatment
arms. Based on an estimated standard deviation of
growth velocity in asthmatic children of 1.5 cm/
yr,8,16 the sample size required to detect a
treatment difference of 0.8 cm/yr (approximately
1/3 of an inch) with 90% power was estimated to be
74 evaluable patients/treatment group. Assuming a
run-in drop-out rate of 40–50% and a withdrawal
rate of 30% during treatment it was estimated that
400 patients were required to be screened, with
the ﬁrst 220 eligible patients to present being
randomly allocated to treatment (competitive
recruitment).
The primary intent-to-treat (ITT) population
comprised all randomised patients who had re-
ceived at least one dose of study medication. The
per-protocol (PP) population comprised only pa-
tients who were compliant with the protocol, who
had sufﬁcient height measurements recorded to
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weeks on treatment with height recorded), con-
sistent height measurements (no height reduction
between visits 41 cm) and height measurements
taken between 6.00 and 10.30 am.
Analyses were performed using SAS version 8.01
and all tests were performed at the 5% level of
signiﬁcance, with treatment differences and asso-
ciated two-sided 95% conﬁdence intervals (CI)
constructed from the ﬁnal model. The mean of
three height measurements was calculated for each
clinic visit. Mean height change from baseline at
each timepoint was calculated from all subjects
with data at that visit and at baseline.
The baseline (annualised) growth velocity for
each treatment group was estimated by regression
of the height during run-in over time. On-treatment
growth velocity (derived from regression of height
during the treatment period over time) was
compared between the two treatment groups using
a mixed effects model. This comparison was
repeated on the PP population for conﬁrmatory
purposes. Factors to be included in the model were
selected using a stepwise regression model from
the following: baseline height, baseline weight,
age, sex, race, socio-economic status and pre-
dicted adult height. The ﬁnal model included
random effect terms for subject and the subject-
by-time interaction, and ﬁxed effect terms for
treatment, time, treatment-by-time interaction,
baseline growth velocity, age, sex, baseline weight
and race. Treatment-by-time-by-covariate interac-
tion terms were investigated. Standard deviation
scores (SDS) were not used to analyse growth
velocity as standard data were not available for
all populations studied.
The proportion of patients experiencing at least
one exacerbation, the percentage of symptom-free
days/nights and the percentage of days/nights with
no use of rescue medication were compared
between treatment groups using a logistic regres-
sion model, adjusting for age, sex and the relevant
baseline value. All other parameters were analysed
using analysis of covariance, adjusting for age, sex
and the relevant baseline value. The values of
urinary free cortisol (nmol/umol creatinine) were
log-transformed to satisfy normality assumptions.Results
Study population
Of the 400 patients entering run-in, 233 were
randomised to treatment with FP or BUD (Fig. 1).The main reason for exclusion during run-in was
that the randomisation target had already been
reached (61/167). Ninety-seven patients were
excluded from the PP analysis, 44 in the FP group
and 52 in the BUD group (Fig. 1). The main reason
for exclusion was growth velocity or height
outside the inclusion/exclusion centiles at visit 1
or 3 due to miscalculation of eligibility (16/44 FP,
25/52 BUD).
Baseline characteristics were similar between
the groups except that slightly more patients on FP
had been diagnosed with asthma for X5 years
(Table 1). Mean percentage of symptom-free days
assessed at each visit during the run-in period was
similar between FP (72–75%) and BUD (71–76%).
Median exposure to the study drug was 365 days in
each group, with a mean of 341(785 SD) days for
FP; and 324 (7110) for BUD. The minimum
treatment period deﬁned by the protocol (51
weeks) was achieved by 74% FP and 72% BUD
patients, and 90% FP and 85% BUD received at least
40 weeks of treatment [Visit 7]. Systemic steroid
use (oral, intravenous or intramuscular) during the
treatment period was more frequent in the BUD
than the FP group (15 vs 6 occasions), while
xanthine use was similar (11 on FP, 10 on BUD).Impact on growth
ITT population
Mean height values at each timepoint are shown in
Fig. 2. During the run-in phase (visits 1–3), the
mean absolute change in height in the ITT popula-
tion was 3.0 cm [SD 0.6 cm] in both the FP (n ¼ 114)
and BUD (n ¼ 119) groups (Fig. 3). Annualised
baseline growth rates were similar between treat-
ment groups, with a mean growth velocity on FP
5.9 cm/yr [SD 1.1] vs BUD 6.0 cm/yr [SD 1.2]). During
treatment, mean unadjusted height change from
baseline (visit 3) to week 52 in the ITT population
was 5.6 cm [71.3], n ¼ 104 on FP compared with
4.7 cm [71.5], n ¼ 101, on BUD. Higher growth on
FP was still seen after adjusting for baseline growth
velocity, age, sex, race and baseline weight, with a
mean growth velocity in the FP group of 5.5 cm/yr
(standard error [SE] 1.3mm/yr; n ¼ 109) compared
with 4.6 cm/yr (SE 1.5mm/yr; n ¼ 111) in the BUD
group. This represented a statistically signiﬁcant
treatment difference in favour of FP of 0.9 cm/yr
(95% CI 0.5, 1.3 cm/yr; Po0:001). The difference in
growth velocities increased over the 12 months.
The majority of children receiving FP grew around
5.0–7.0 cm/yr, whereas the majority of those
receiving BUD grew in the range of 3.0–5.0 cm/yr
(Fig. 4).
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Enrolment 
Allocation 
Follow-up 
Analysis 
Assessed for 
eligibility (n=400) 
Excluded (n=167) 
Randomization complete 
(n=61) 
Not eligible (n=30) 
Protocol violation (n=28) 
Lost to follow-up (n=23) 
Consent withdrawn (n=14)
Adverse event (n=9) 
Other reasons (n=2) 
Randomized (n=233)
Allocated to fluticasone 
propionate (n=114)
Received allocated 
intervention (n=114) 
Allocated to budesonide
(n=119) 
Received allocated 
intervention (n=119) 
Premature discontinuation 
(n=12) 
Adverse event (n=1) 
Protocol violation (n=4) 
Consent withdrawn (n=1) 
Lost to follow-up (n=2) 
Other reasons (n=4)
Premature discontinuation 
(n=19) 
Adverse event (n=0) 
Protocol violation (n=13) 
Consent withdrawn (n=1)
Lost to follow-up (n=2) 
Other reasons (n=3)
Analysed [ITT population] (n=114)
Per protocol population (n=70) 
Primary reasons for exclusion: 
Height or growth velocity outside 
protocolled range at visit 1 or 3 (n=16) 
Data quality/precision concerns (n=9) 
Valid height measurements over <28 
weeks and/or <4 occasions (n=6) 
Entered puberty (n=5) 
Reversibility <15% (n=6) 
Other (n=2) 
Analysed [ITT population] (n=119)
Per protocol population (n=67) 
Primary reasons for exclusion: 
Height or growth velocity outside 
protocolled range at visit 1 or 3 (n=25) 
Data quality/precision concerns (n=7) 
Valid height measurements over <28 
weeks and/or <4 occasions (n=7) 
Entered puberty (n=4) 
Reversibility <15% (n=4) 
Other (n=5) 
Figure 1 Flowchart showing patients’ progress throughout the study.
A.C. Ferguson et al.122PP population
Mean height change during run-in for the PP
population was 2.9 cm (SD 0.3, n ¼ 70) for the FP
group and 3.0 cm (SD 0.4, n ¼ 65) for the BUD group.
The difference in mean adjusted growth velocity
between the two groups observed in the ITT
population was conﬁrmed in the PP population
(5.3 [SE 0.1] cm, n ¼ 70 for FP vs 4.3 [SE 0.1] cm,
n ¼ 66 for BUD), a statistically signiﬁcant treat-
ment difference of 1.0 cm/yr in favour of FP (95% CI
0.6, 1.4 cm/year; Po0:001).Efﬁcacy outcomes
The main efﬁcacy outcomes are summarised in
Table 2. No signiﬁcant differences were observed
between FP- and BUD-treated subjects in the mean
change over the treatment period for PEFR, or for
FVC and FEV1 at each visit with the exception of
week 16 FEV1 data and weeks 16 and 52 FVC data.
Slightly smaller mean increases in FVC were
observed in FP-treated subjects at weeks 16
(0.063 vs 0.137 L, P ¼ 0:017) and 52 (0.185 vs
0.270 L, P ¼ 0:042) and a smaller increase in FEV1 inFP-treated subjects at week 16 (0.063 vs 0.149,
P ¼ 0:001). The values at week 16 for FP treated
subjects were lower than expected from values at
weeks 4 and 28 (Fig. 5).
The odds of reporting at least one exacerbation
during the study were lower on FP than BUD, but
the difference was not stistically signiﬁcant (odds
ratio [OR] ¼ 0.614; 95% CI 0.323, 1.149; P ¼ 0:131)
(Table 2). Similar ﬁndings were observed for severe
exacerbations (OR ¼ 0.426; 95% CI 0.111, 1.370;
P ¼ 0:171). There was no signiﬁcant difference
observed between the two treatments with regard
to the odds of experiencing 100% versus o100%
symptom-free days or nights (i.e. no symptoms
versus any symptoms), nor with regard to the odds
of experiencing 100% versus o100% salbutamol-
free days or nights. The proportion of patients with
asthma-related, unscheduled healthcare contacts
was equal in the two groups (22%).Other outcomes
Treatment with either FP or BUD was well tolerated
(Table 3). While 92 (81%) FP- and 84 (71%)
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Table 1 Baseline patient characteristics (ITT population).
FP (n ¼ 114) BUD (n ¼ 119)
Males, n (%) 77 (68) 83 (70)
Females, n (%) 37 (32) 36 (30)
Age, years
Mean (SD) 7.2 (1.0) 7.4 (1.0)
6–7 years (%) 69 (61) 67 (56)
8–9 years (%) 45 (39) 52 (44)
Ethnic origin, n (%)
White 61 (54) 67 (56)
American Hispanic 46 (40) 47 (39)
Black/Asian/other 7 (6) 5 (4)
Height, cm
Visit 1 mean (SD) 125.5 (7.5) 126.3 (7.8)
Visit 3 mean (SD) 128.5 (7.4) 129.3 (7.8)
Duration of asthma, n (%)
o2 years 16 (14) 13 (11)
2 years to o5 years 48 (42) 63 (53)
X5 years 49 (43) 43 (36)
Patients with exacerbations requiring oral corticosteroids in previous 6 months, n (%)
0 84 (74) 94 (79)
X1 29 (25) 25 (21)
Patients with hospitalisations in the last 6 months, n (%)
0 95 (84) 100 (84)
X1 18 (16) 19 (16)
Mean % predicted morning FEV1 at visit 1 (SD) 90.2 (15.6) 92.3 (17.9)
Mean morning PEF, L/min at visit 1 (SD) 190.1 (52.3) 195.4 (57.0)
Mean morning PEF % reversibility at visit 1 (SD) 27.9 (17.0) 28.0 (15.5)
All data are at visit 1 unless speciﬁed.
Data only available for 113 patients in the FP group for these parameters.
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Figure 2 Mean height over time (ITT population). All
values are means of those with data at that visit.
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Figure 3 Mean change in height over time (ITT popula-
tion). Patient numbers at each timepoint are those with
data at that visit and at baseline.
Growth velocity with inhaled corticosteroids in children 123BUD-treated patients experienced adverse events
during the treatment phase, in only 3 (3%) and 2
(2%) patients, respectively, they were considered
to be treatment-related. Serious adverse events
were reported during treatment by 1 (o1%) FP-
and 4 (3%) BUD-treated patients, and during run-inby 4 and 2 patients, respectively. Vital signs
remained normal in all patients and no lens
opacities were reported. Only three patients (2
FP, 1 BUD) showed clinical signs of oropharyngeal
candidiasis and none of these were conﬁrmed by
swab culture.
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Figure 4 Frequency distribution of growth velocity
during (A) run-in and (B) treatment (ITT population).
A.C. Ferguson et al.124Overnight urinary free cortisol levels (adjusted
for creatinine, nmol/umol creatinine) were similar
in the two groups at baseline (FP: 3.8, n ¼ 112, and
BUD: 4.0, n ¼ 111). At weeks 26 and 52 adjusted
geometric mean values were 3.3 and 3.8, respec-
tively for FP (n ¼ 98 and 89) compared with 3.0
and 4.0, respectively for BUD (n ¼ 97 and 85). The
ratio of the treatment difference between groups
was not signiﬁcant at week 26 (1.10, 95% CI
0.87–1.39) nor at week 52 (0.97, 95% CI0.75–
1.26). The adjusted mean changes in lumbar
spine BMD between baseline and week 52 in
the FP and BUD groups were +0.0070 g/cm2
(n ¼ 42) and 0.0005 g/cm2 (n ¼ 38), respectively.
The between-group difference was not statistically
signiﬁcant (0.0075 g/cm2; 95% CI 0.0332, 0.0482;
P ¼ 0:715).Discussion
Our study has shown that growth velocity over a 12-
month treatment period is signiﬁcantly greater inchildren treated with FP than with BUD despite
having a similar growth velocity during the 26-week
run-in period. At the same time asthma control as
assessed by lung function, frequency of exacerba-
tions, symptoms and use of reliever medications
showed no consistent difference between the
treatments, although the study was not powered
to examine these. Safety measures showed no
signiﬁcant differences between the groups.
The main objective of the study was to assess
differences in growth velocity between children in
the FP and BUD treatment arms, rather than to
determine their absolute growth velocities (i.e.
compared to no treatment). No formal comparison
of growth velocity slopes between the run-in and
treatment periods could be made as baseline
growth velocities were derived from fewer visits
during a shorter time period than the on-treatment
growth velocities. However, growth velocities dur-
ing the run-in and treatment periods in the FP
group were very similar, suggesting a minimal
absolute effect with FP. This was not the case in
the BUD group, as indicated by a clear downward
shift in growth velocity distribution following the
introduction of BUD treatment.
Both groups were well balanced at baseline for
factors known to affect growth velocity such as
age, sex and pubertal status, although the mean
Visit 1 height was lower for FP than BUD. Baseline
height was considered as an adjustment factor but
found to be less signiﬁcant than other factors,
while adjustment was made for run-in growth
velocity in the analysis, on a patient-by-patient
basis. Duration of inhaled corticosteroid treatment
was similar between groups, and compliance with
treatment was comparable (according to the
recorded data) due to the double-blind, double
dummy design. Subjects in the BUD group required
systemic steroid treatment more often than the FP
group. This may have contributed slightly to the
reduction in growth velocity compared with FP and
may also have affected the efﬁcacy comparison,
but cannot by itself explain the reduced growth
velocity in most of the subjects, nor the main-
tenance of the reduced rate over the 1 year
treatment period.
Our study comes closer than any previous to
meeting the key design criteria identiﬁed in a
recent review of growth studies in asthma, includ-
ing an ICS-free run-in period, study duration of 12
months, stadiometry, and height measured at the
same time of day at each visit.13 Children with
extremes of stature or growth velocity were
excluded to avoid obscuring any treatment effects
by underlying growth abnormalities, as were those
with a pubertal growth spurt. Less than 4% of those
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Table 2 Efﬁcacy parameters (ITT population).
FP
(n ¼ 114)
BUD
(n ¼ 119)
Difference (95% CI) P-value
Adjusted mean change over
treatment, mean (SE)
Morning PEFR, L/min (n ¼ 95)
29.7 (3.4)
(n ¼ 88)
26.2 (3.5)
3.4 (5.7, 12.6) 0.460
Evening PEFR, L/min n ¼ 93 32.4
(3.2)
n ¼ 89 25.4
(3.3)
7.0 (1.7, 15.8) 0.113
Adjusted mean change at week 52 (n ¼ 96) (n ¼ 97)
FEV1, L 0.19 (0.03) 0.25 (0.03) 0.05 (0.13, 0.02) 0.154
FVC, L 0.19 (0.03) 0.27 (0.03) 0.09 (0.17, 0.003) 0.042
FEV1/FVC ratio 0.02 (0.01) 0.01 (0.01) 0.007 (0.01, 0.02) 0.386
Odds ratio (95% CI)
Patients with exacerbations, n (%) n ¼ 114 n ¼ 119
0 85 (75) 81 (68) 0.61 (0.32, 1.15) 0.131
X1 29 (25) 38 (32)
Patients with following proportions
of symptom-free days, n (%)
(n ¼ 92) (n ¼ 89)
0% 1 (1) 0
40–25% 2 (2) 0 1.08 (0.58, 2.03)y 0.799
425–50% 4 (4) 1 (1)
450–75% 9 (10) 10 (11)
475–99% 31 (34) 35 (39)
100% 45 (49) 43 (48)
Patients with following proportions
of symptom-free nights, n (%)
(n ¼ 94) (n ¼ 88)
0% 2 (2) 0
40–25% 1 (1) 0 0.68 (0.36, 1.28)y 0.232
425–50% 3 (3) 1 (1)
450–75% 6 (6) 6 (7)
475–99% 35 (37) 30 (34)
100% 47 (50) 51 (58)
Patients with following proportions
of days requiring no salbutamol, n
(%)
(n ¼ 92) (n ¼ 89)
0% 0 1 (1)
40–25% 1 (1) 0 1.54 (0.82, 2.93)y 0.180
425–50% 3 (3) 1 (1)
450–75% 9 (10) 12 (13)
475–99% 27 (29) 29 (33)
100% 52 (57) 46 (52)
Patients with following proportions
of nights requiring no salbutamol, n
(%)
(n ¼ 93) (n ¼ 88)
0% 0 0
40–25% 0 0 1.05 (0.57, 1.96)y 0.866
425–50% 2 (2) 2 (2)
450–75% 3 (3) 4 (5)
475–99% 29 (31) 28 (32)
100% 59 (63) 54 (61)
All analyses adjusted for baseline, age and sex. All data presented are based on the number of patients with data for both
baseline and treatment periods under analysis. Clinic visit lung function values inﬂuenced by salbutamol use in 6 h prior to
assessment replaced using interpolation on values from the two closest visits not affected by salbutamol use (except for the
baseline visit where affected values were treated as missing).
yOdds ratios (95% CI) for 100% vs 0–99% categories.
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matching of the groups’ baseline characteristics
and the inclusion of age as an adjustment factor in1.4
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Figure 5 Lung function during the 12-month treatment
period (ITT population). All values are means of those
with data at that visit.
Table 3 Adverse events (ITT population).
Patients with adverse events, n (%)
Patients with common adverse events, n (%)
Ear, nose and throat
Lower respiratory
Non-site speciﬁc
Skin
Gastrointestinal
Patients with drug-related adverse events, n (%)
Ear, nose and throat
Lower respiratory
Neurology
Non-site speciﬁc
Patients with serious adverse events, n (%)
Lower respiratory
Drug interaction, overdose and trauma
Skin
Urology
Patients with any adverse event leading to withdrawal, n
Lower respiratory (asthma)
Patients with abnormal ophthalmic examination, n (%)
Patients with clinical oropharyngeal candidiasis, n (%)
Adverse events occurring in X10% of patients in either treatmthe analysis should have minimised any effect on
growth assessments. The majority of subject with-
drawals during the run-in phase were unrelated to
eligibility for the study, while exclusions from the
PP population were mainly a result of miscalcula-
tions of eligibility, occurred early in the treatment
period, and were similar in both treatment groups.
Sufﬁcient power was retained to detect differences
in growth velocity in the PP population, which
conﬁrmed the ﬁndings in the ITT population.
Our study was conducted across several countries
in children with asthma who may not grow at the
same rate as ‘normal’ children and in whom,
therefore, the preferred measurement was growth
velocity with adjustment for age, sex and other
appropriate covariates in the model. Reference
data for growth velocity were not available for
most countries in which the study was conducted.
We therefore used those based on healthy British
children (from 1965).15 This might have affected
the study populations recruited in different coun-
tries as the British percentiles, when applied to
other children, might deﬁne subtly different sec-
tions of the local population. The effect should be
consistent between the treatment groups however,
and not have biased the outcome. The use of
standard deviation scores, which reference actual
growth velocity to a suitable normal growth rateFP (n ¼ 114) BUD (n ¼ 119)
92 (81) 84 (71)
58 (51) 36 (30)
56 (49) 59 (50)
18 (16) 13 (11)
11 (10) 13 (11)
12 (11) 9 (8)
2 (2) 0
1 (o1) 1 (o1)
1 (o1) 0
0 1 (o1)
0 2 (2)
0 1 (o1)
1 (o1) 0
0 1 (o1)
(%)
1 (o1) 0
0 0
2 (2) 1 (o1)
ent group.
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as there are no population-speciﬁc standard re-
ference data for most of the countries studied.
The results of our study conﬁrm prior reports in
which FP at recommended doses has been shown to
be as effective as BUD and beclomethasone
diproprionate when used at half the microgram
dose, and to have negligible oral bioavailabil-
ity.12,17–19 Both treatment groups showed clinically
relevant improvements from baseline and similar
overall efﬁcacy. The lack of between-group differ-
ences in FVC and FEV1 at most clinic visits, and in
FEV1/FVC ratio at all visits, suggests that the
signiﬁcant differences observed at weeks 16 and
52 are unlikely to be clinically relevant, particu-
larly as the rate of exacerbations tended to favour
FP slightly and other markers of efﬁcacy were
similar.
There was no overall suppression of cortisol
secretion by either FP or BUD, consistent with
previous studies at these doses.12,20–23 The reduc-
tion in growth velocity in the absence of cortisol
suppression is also consistent with previous stu-
dies7,24 and may be explained by the suppression of
pituitary growth hormone release by ICS as a result
of increased hypothalamic somatostatin tone.25 In a
study by Agertoft and Pedersen26 in 24 children,
however, BUD at 400 mg day1 and FP at both 200
and 400 mg day1 signiﬁcantly reduced 24-h urinary
cortisol levels, with reduced growth following BUD
(but not FP) at these doses. This study used a
different collection period and assay method for
cortisol, however, and knemometry rather than
stadiometry to measure growth, making a direct
comparison difﬁcult.
Recent pharmacokinetic/pharmacodynamic
modelling of the propensity for steroids to cause
growth effects and cortisol changes concluded that
growth effects are unlikely to be seen in the
absence of cortisol suppression.27 The model used
predicts cortisol suppression by BUD 400 mg day1 of
15–20% and by FP200 mg day1 of 3–5% [personal
communication], and hence the anticipated differ-
ence between them is likely to be o15%. Changes
of this magnitude are within the range of variability
observed in our study, however, hence the lack of
observed difference is not surprising. If we had
used the measure recommended in the paper27 of
24-h serum cortisol AUC then low levels of cortisol
suppression might have been seen. Provocation
tests such as the insulin tolerance test or short
synacthen test may be more physiologically infor-
mative than simple cortisol secretion, but it was
not considered feasible to perform these tests in
large numbers of young children across such a
geographically diverse environment.The assay used to measure cortisols can also
inﬂuence results as described by Fink et al.,28 who
showed that variations in readings greater than the
typical treatment effect of an inhaled steroid can
be produced simply by changing the assay used. All
the immunoassays tested were subject to this
variability and the major metabolites of BUD (6b-
hydroxybudesonide and 16b-hydroxyprednisolone)
can cross-react with antibodies against cortisol,
increasing the apparent levels of cortisol present
and potentially masking cortisol suppression. Chro-
matography-based assays such as the one used in
our study avoid this sort of variability and cross-
reactivity and are considered the gold standard for
cortisol measurement.
The skeletal effects as assessed by BMD showed
no impairment by either drug and possibly a lesser
effect from FP, but a longer assessment period
would probably be required to show a statistically
signiﬁcant difference.
On-treatment ENT adverse events were higher in
the FP compared with the BUD group (51% vs 30%).
Pre-treatment ENT events were also higher,
although not to the same extent (33% vs 26%).
The main differences on treatment were accounted
for by the incidences of rhinitis (14% vs 8%) and
pharyngitis/throat infection (10% vs 3%) but none of
these events were attributed to treatment by the
investigator. The rates of oropharyngeal candidiasis
were low and similar in both groups. Other
measures of safety were similar between groups
and the safety proﬁle of both treatments was good.
Lack of a placebo arm prevented measurement of
the absolute growth effect of either FP or BUD, but
18 months of placebo therapy would be unethical in
children who by the time of allocation to treatment
required long-term ICS therapy to meet an appro-
priate standard of care. Despite this the run-in
period did provide a crude indication of the
absolute effect of treatment. The inclusion of
children from different countries may increase
the variability of measurements but should not
bias the outcome in favour of one treatment. The
effect of nationality could not be assessed, due to
insufﬁcient subjects per country, but the ethnic
distribution of subjects was similar in both treat-
ment groups and all measurements were standar-
dised. The multi-national nature of the study
suggests the results would be valid in a range of
populations, and any treatment effects resulting
from a higher dose per body weight in younger
children should be similar in each treatment group
as the age distribution was similar.
The results of our study are consistent with
previous placebo- and cromone-controlled studies
of FP and BUD on growth in children. In a study
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day), BUD (400 mg/day) and cromone a signiﬁcantly
reduced height standard deviation score was
observed with BUD vs baseline (Po0:01), but not
with either FP or cromone.9 Modest and transient
reductions in growth velocity with BUD have been
reported in a study comparing nebulised BUD
500 mg/day with non-ICS therapy,29 and in the large
Childhood Asthma Management Plan study compar-
ing BUD (400 mg/day) with nedocromil and placebo,
in which the effect diminished after a year.11 In a
recent, large, placebo-controlled study of prepu-
bertal children inhaling low dose BUD (200 mg/day)
growth velocity was reduced by 0.58 cm/yr during
the ﬁrst year of treatment, but the study was not
designed to measure the absolute effect of BUD on
growth.30 A large-scale study comparing FP (100 or
200 mg/day) with placebo reported no overall
difference between the three groups,16 although
a separate analysis showed a small reduction in
growth rate with the 200 mg/day dosage.31 The
long-term effects of FP (200 mg/day) and nedocro-
mil (8mg/day) on BMD and growth were found to be
similar in a 2-year study of children aged 6–14
years.32
No conclusions about the effect on ﬁnal height
can be drawn from our data, but the height
differential between the FP and BUD groups
progressively increased throughout the year on
treatment. On the other hand, a prospective but
open, non-randomised study with BUD indicated no
effect on ﬁnal height compared with healthy
controls despite decreased growth during the ﬁrst
2 years of treatment.33 Long-term prospective
randomised trials comparing the effects of differ-
ent ICS on ﬁnal height are needed to deﬁnitively
settle this question.
Our study demonstrates less impairment of
growth velocity by FP compared with BUD, but
similar efﬁcacy and safety over a 12-month treat-
ment period. These ﬁndings indicate that ICS differ
in their effects on growth and suggest that, when
choosing an ICS for childhood asthma, the physician
should carefully consider the risk/beneﬁt proﬁle of
ICS as well as the general precautionary measures
of titrating to the lowest possible dose and
monitoring growth regularly.Acknowledgements
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